Reading...
Play button
Play button
Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
17 Cards in this Set
- Front
- Back
|
what is pharmacogenomics
|
science of inherited variations in genes
to predict a patients response to a med, good or bad it correlates the expression of SNP with drug efficacy/toxicity |
|
|
pt's with HLA-B 5701 allele should not be given these meds
|
abacavir (ziagen), (epzicom) ( trizivir)
|
|
|
pt's on Plavix should be tested for which gene mutation
|
cyp 2c19
|
|
|
if Asian and taking carbamazepine which test needs to be done first
what is the adverse effect if this expression is present and med started |
HLA 1502
Toxic Epidermal Necrosis (TEN) and SJS |
|
|
who is a candidate for trastuzamab
|
HER2 + patients
91 test must be 2+ or 3+, (+1 are weak tumors and don't respond) |
|
|
Crizotinib
what test needs to be done |
anaplastic lymphoma kinase (ALK) test
patient needs to be positive for med to work |
|
|
vemurafenib testing
|
BRAFV600E mutation, need this mutation for med to work
for metastatic melanoma |
|
|
cetuximab testing
|
K-raS MUTATION indicates a poor response
|
|
|
maraviroc testing
|
tropism test, pt's with CCR-5 HIV can use this
|
|
|
azathiopurine and mercaptopurine testing
|
monitor for TPMT, thiopurine methyltransferase,
pt's with this deficenecy has increased risk of myleosuppresion |
|
|
Rituximab testing
|
CD-20 receptor status positive on cell surface, pt needs this for med to work
|
|
|
cepecitabine
5-FU TESTING |
Dihydropyrimidine dehydrogenase DPD
a deficenecy of this increases toxicity |
|
|
phenytoin testing
|
HLA-B 1502 if Asian
if positive don't use, risk of TEN + SJS |
|
|
ATOMOXETINE testing
|
2C9 poor metabolizers may have higher levels, 5 fold
|
|
|
allopurinol testing
|
HLA-B 5801, severe cutaneous infxn can occur
|
|
|
codeine testing
|
2d6 extensive metabolizers will, increase the conversion to morphine
|
|
|
warfarin testing
|
loss of functioning CYP 2C9*2 and 2C9*3 can increase bleeds and need for monitoring
and the VKORC1 gene, loss of function of this gene requires a dose reduction |
